These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 22675171)

  • 1. Progenitor-like traits contribute to patient survival and prognosis in oligodendroglial tumors.
    Ng FS; Toh TB; Ting EH; Koh GR; Sandanaraj E; Phong M; Wong SS; Leong SH; Kon OL; Tucker-Kellogg G; Ng WH; Ng I; Tang C; Ang BT
    Clin Cancer Res; 2012 Aug; 18(15):4122-35. PubMed ID: 22675171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
    Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
    Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors.
    McDonald JM; See SJ; Tremont IW; Colman H; Gilbert MR; Groves M; Burger PC; Louis DN; Giannini C; Fuller G; Passe S; Blair H; Jenkins RB; Yang H; Ledoux A; Aaron J; Tipnis U; Zhang W; Hess K; Aldape K
    Cancer; 2005 Oct; 104(7):1468-77. PubMed ID: 16088966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors.
    Ueki K; Nishikawa R; Nakazato Y; Hirose T; Hirato J; Funada N; Fujimaki T; Hojo S; Kubo O; Ide T; Usui M; Ochiai C; Ito S; Takahashi H; Mukasa A; Asai A; Kirino T
    Clin Cancer Res; 2002 Jan; 8(1):196-201. PubMed ID: 11801559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features.
    van den Bent MJ; Looijenga LH; Langenberg K; Dinjens W; Graveland W; Uytdewilligen L; Sillevis Smitt PA; Jenkins RB; Kros JM
    Cancer; 2003 Mar; 97(5):1276-84. PubMed ID: 12599236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluorescent in situ hybridization on isolated tumor cell nuclei: a sensitive method for 1p and 19q deletion analysis in paraffin-embedded oligodendroglial tumor specimens.
    Gelpi E; Ambros IM; Birner P; Luegmayr A; Drlicek M; Fischer I; Kleinert R; Maier H; Huemer M; Gatterbauer B; Anton J; Rössler K; Budka H; Ambros PF; Hainfellner JA
    Mod Pathol; 2003 Jul; 16(7):708-15. PubMed ID: 12861068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker?
    Weller M; Berger H; Hartmann C; Schramm J; Westphal M; Simon M; Goldbrunner R; Krex D; Steinbach JP; Ostertag CB; Loeffler M; Pietsch T; von Deimling A;
    Clin Cancer Res; 2007 Dec; 13(23):6933-7. PubMed ID: 18056167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular analysis of chromosome 1, 10 and 19 abnormalities in human oligodendroglial tumors: relationship between frequency of LOH grade, age and gender.
    Gresner SM; Rieske P; Wozniak K; Piaskowski S; Jaskolski DJ; Skowronski W; Golanska E; Sikorska B; Liberski PP
    Clin Neuropathol; 2006; 25(1):18-24. PubMed ID: 16465770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MR imaging characteristics of oligodendroglial tumors with assessment of 1p/19q deletion status.
    Sherman JH; Prevedello DM; Shah L; Raghavan P; Pouratian N; Starke RM; Lopes MB; Shaffrey ME; Schiff D
    Acta Neurochir (Wien); 2010 Nov; 152(11):1827-34. PubMed ID: 20711790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene expression profiles associated with treatment response in oligodendrogliomas.
    French PJ; Swagemakers SM; Nagel JH; Kouwenhoven MC; Brouwer E; van der Spek P; Luider TM; Kros JM; van den Bent MJ; Sillevis Smitt PA
    Cancer Res; 2005 Dec; 65(24):11335-44. PubMed ID: 16357140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Diagnostic and prognostic roles of loss of CIC protein expression in oligodendroglial tumors].
    Liu CC; Zhang LY; Wang LM; Wang DD; Fu YJ; Cai YN; Lu DH; Piao YS
    Zhonghua Bing Li Xue Za Zhi; 2017 Oct; 46(10):679-683. PubMed ID: 29050068
    [No Abstract]   [Full Text] [Related]  

  • 12. Expression of hypoxia-related tissue factors correlates with diminished survival of adjuvantly treated patients with chromosome 1p aberrant oligodendroglial neoplasms and therapeutic implications.
    Birner P; Preusser M; Gelpi E; Berger J; Gatterbauer B; Ambros IM; Ambros PF; Acker T; Plate KH; Harris AL; Hainfellner JA
    Clin Cancer Res; 2004 Oct; 10(19):6567-71. PubMed ID: 15475445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between genetic alteration and long-term clinical outcome of patients with oligodendroglial tumors, with identification of a consistent region of deletion on chromosome arm 1p.
    Hashimoto N; Murakami M; Takahashi Y; Fujimoto M; Inazawa J; Mineura K
    Cancer; 2003 May; 97(9):2254-61. PubMed ID: 12712480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oligodendrogliomas: clinical significance of 1p and 19q chromosomal deletions.
    Sonabend AM; Lesniak MS
    Expert Rev Neurother; 2005 Nov; 5(6 Suppl):S25-32. PubMed ID: 16274268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Diagnostic and prognostic values of 1p and 19q deletions in adult gliomas: critical review of the literature and implications in daily clinical practice].
    Fontaine D; Vandenbos F; Lebrun C; Paquis V; Frenay M
    Rev Neurol (Paris); 2008; 164(6-7):595-604. PubMed ID: 18565359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of molecular and clinical factors on patient outcome in oligodendroglioma from 20 years' experience at a single centre.
    Parkinson JF; Afaghi V; Payne CA; Buckland ME; Brewer JM; Biggs MT; Little NS; Wheeler HR; Cook RJ; McDonald KL
    J Clin Neurosci; 2011 Mar; 18(3):329-33. PubMed ID: 21247767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. alpha-Internexin expression identifies 1p19q codeleted gliomas.
    Ducray F; Crinière E; Idbaih A; Mokhtari K; Marie Y; Paris S; Navarro S; Laigle-Donadey F; Dehais C; Thillet J; Hoang-Xuan K; Delattre JY; Sanson M
    Neurology; 2009 Jan; 72(2):156-61. PubMed ID: 19139367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of oligodendroglioma specific chromosomal copy number changes in the glioblastoma MI-4 cell line by array-CGH and FISH analyses.
    Magnani I; Moroni RF; Roversi G; Beghini A; Pfundt R; Schoenmakers EF; Larizza L
    Cancer Genet Cytogenet; 2005 Sep; 161(2):140-5. PubMed ID: 16102584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. α-Internexin in the diagnosis of oligodendroglial tumors and association with 1p/19q status.
    Eigenbrod S; Roeber S; Thon N; Giese A; Krieger A; Grasbon-Frodl E; Egensperger R; Tonn JC; Kreth FW; Kretzschmar HA
    J Neuropathol Exp Neurol; 2011 Nov; 70(11):970-8. PubMed ID: 22002423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Influence of molecular-genetic factors on prognosis in patients with oligodendroglial tumors].
    Absaliamova OV; Korshunov AG; Loshakov VA; Kobiakov GL; Golanov AV; Urakov SV; Amanov RD; Lichinitser MR
    Zh Vopr Neirokhir Im N N Burdenko; 2009; (1):17-23; discussion 23-4. PubMed ID: 19507310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.